Tarsus Pharmaceuticals Inc. (TARS) News

Tarsus Pharmaceuticals Inc. (TARS): $13.50

0.46 (+3.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TARS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 391

in industry

Filter TARS News Items

TARS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest TARS News From Around the Web

Below are the latest news stories about Tarsus Pharmaceuticals Inc that investors may wish to consider to help them evaluate TARS as an investment opportunity.

Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer

Dr. Trevejo brings over 20 years of clinical development experience to Tarsus as it advances development of TP-03, the first potential treatment for Demodex blepharitis, and its pipeline programs IRVINE, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of José Trevejo, M.D., Ph.D

Yahoo | February 3, 2022

Tarsus completes enrollment in phase 3 study in eyelid disease; secures $175M credit line

Tarsus Pharmaceuticals (TARS) completed enrollment in a second phase 3 trial, dubbed Saturn-2, of TP-03 (lotilaner ophthalmic solution, 0.25%) for patients with Demodex blepharitis;

Seeking Alpha | February 2, 2022

Tarsus to Host Eye Care Leaders Webcast on Unmet Needs in Demodex Blepharitis and Potential of TP-03

Revolutionizing Treatment for Demodex Blepharitis Patients event to feature Eric Donnenfeld, M.D.; Paul Karpecki, O.D.; and Elizabeth Yeu, M.D. Webcast scheduled for Tuesday, February 8, 2022 at 9 a.m. Pacific Time IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live

Yahoo | February 2, 2022

Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures $175 Million Credit Facility

Topline data expected in April 2022 from Saturn-2, the second Phase 3 pivotal trial of TP-03 and NDA submission remains on track for this year Credit facility with Hercules Capital and Silicon Valley Bank provides availability of non-dilutive capital IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today

Yahoo | February 2, 2022

Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors

Dr. Yeu brings over 20 years of eye care experience, and is a highly regarded leader in clinical care and new product innovation IRVINE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Elizabeth Yeu, M.D. to its Board of Directors. Dr. Yeu will continue to serve as Tarsus’ Ch

Yahoo | January 4, 2022

H.C. Wainwright Initiates a Buy Rating on Tarsus Pharmaceuticals (TARS)

Tarsus Pharmaceuticals (TARS – Research Report) received a Buy rating and a $40.00 price target from H.C. Wainwright analyst Oren Livnat today. The company's shares closed last Monday at $24.13, close to its 52-week low of $21.00. According to TipRanks.com, Livnat is a 2-star analyst with an average return of 1.0% and a 41.3% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Verrica Pharmaceuticals, and Zynerba Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tarsus Pharmaceuticals with a $57.00 average price target.

Howard Kim on TipRanks | December 21, 2021

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Nuveen Asset Management LLC

Nuveen Asset Management LLC lifted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 73.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,723 shares of the companys stock after buying an additional 10,891 shares during the quarter. Nuveen Asset [] The post Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Nuveen Asset Management LLC appeared first on ETF Daily News .

ETF Daily News | November 30, 2021

Oppenheimer Comments on Tarsus Pharmaceuticals, Inc.s FY2021 Earnings (NASDAQ:TARS)

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Equities research analysts at Oppenheimer issued their FY2021 earnings estimates for Tarsus Pharmaceuticals in a research note issued to investors on Monday, November 22nd. Oppenheimer analyst F. Brisebois expects that the company will post earnings of ($0.48) per share for the year. Oppenheimer currently has a Outperform rating and a []

Dakota Financial News | November 27, 2021

Tarsus Pharmaceuticals (NASDAQ:TARS) Receives New Coverage from Analysts at Oppenheimer

Oppenheimer started coverage on shares of Tarsus Pharmaceuticals (NASDAQ:TARS) in a research note issued to investors on Monday morning, PriceTargets.com reports. The brokerage issued an outperform rating and a $55.00 price objective on the stock. Several other research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Tarsus Pharmaceuticals […]

Dakota Financial News | November 25, 2021

Tarsus to Participate at Upcoming Virtual Investor Conferences

IRVINE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following virtual investor conferences:

Intrado Digital Media | November 23, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6048 seconds.